REGISTERED NUMBER: 09993255 (England and Wales)

Unaudited Financial Statements for the Year Ended 31 March 2018

for

PharmaSEAL International Limited

Contents of the Financial Statements
for the Year Ended 31 March 2018

Company Information
for the Year Ended 31 March 2018

DIRECTORS:	D Cheema N E Rotherham Mercia Fund Management (Nominees) Ltd
SECRETARY:	
REGISTERED OFFICE:	Ingenuity Centre Nottingham University Innovation Park Triumph Rpad Nottingham NG7 2TU
REGISTERED NUMBER:	09993255 (England and Wales)
ACCOUNTANTS:	M Ahmed & Co Chartered Accountants 83 Park Road Chilwell Nottingham NG9 4DE

PharmaSEAL International Limited (Registered number: 09993255)

Balance Sheet
31 March 2018

	Notes	**31.3.18** £	£	31.3.17 as restated £	£
FIXED ASSETS					
Tangible assets	4		**1,652**		-
CURRENT ASSETS					
Debtors	5	**45,479**		6,537	
Cash at bank		**361,707**		70,216	
		407,186		76,753	
CREDITORS					
Amounts falling due within one year	6	**159,116**		157,571	
NET CURRENT ASSETS/(LIABILITIES)			**248,070**		(80,818)
TOTAL ASSETS LESS CURRENT LIABILITIES			**249,722**		(80,818)
CAPITAL AND RESERVES					
Called up share capital	7		**2**		1
Share premium	8		**499,988**		-
Retained earnings	8		**(250,268)**		(80,819)
SHAREHOLDERS' FUNDS			**249,722**		(80,818)

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2018.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2018 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors on 29 May 2018 and were signed on its behalf by:

D Cheema - Director

1. STATUTORY INFORMATION

PharmaSEAL International Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with the provisions of Section 1A "Small Entities" of Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Changes in accounting policies
It has been decided to not capitalise development expenditure. The 2017 accounts have been restated and all development expenditure capitalised and included in intangible assets in 2017 has been transferred to the profit and loss account. Full details are shown the prior year adjustments note.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Computer equipment - 33% on reducing balance

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

continued...

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 5 (2017 - 1) .

4. TANGIBLE FIXED ASSETS

	Plant and machinery etc
	£
COST	
Additions	**2,478**
At 31 March 2018	**2,478**
DEPRECIATION	
Charge for year	**826**
At 31 March 2018	**826**
NET BOOK VALUE	
At 31 March 2018	**1,652**

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	31.3.18	31.3.17 as restated
	£	£
Tax	**41,498**	-
VAT	**3,981**	6,537
	45,479	6,537

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	31.3.18	31.3.17 as restated
	£	£
Trade creditors	**13,734**	12,941
Other creditors	**1,775**	453
Directors' current accounts	**141,999**	137,000
Accrued expenses	**1,608**	7,177
	159,116	157,571

continued...

7. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:

Number:	Class:	Nominal value:	**31.3.18**	31.3.17 as restated
			£	£
100,000	Ordinary	£0.00001	**1**	1
55,554	A Ordinary	£0.00001	**1**	-
			2	1

55,554 A Ordinary shares of £0.00001 each were allotted as fully paid at a premium of £9.0002 per share during the year.

8. RESERVES

	Retained earnings	**Share premium**	**Totals**
	£	**£**	**£**
At 1 April 2017	**(80,819)**	**-**	**(80,819)**
Deficit for the year	**(169,449)**		**(169,449)**
Cash share issue	**-**	**499,988**	**499,988**
At 31 March 2018	**(250,268)**	**499,988**	**249,720**